GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Accounts Payable

Exelixis (FRA:EX9) Accounts Payable : €24 Mil (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Accounts Payable?

Exelixis's Accounts Payable for the quarter that ended in Mar. 2024 was €24 Mil.

Exelixis's quarterly Accounts Payable increased from Sep. 2023 (€25 Mil) to Dec. 2023 (€31 Mil) but then declined from Dec. 2023 (€31 Mil) to Mar. 2024 (€24 Mil).

Exelixis's annual Accounts Payable increased from Dec. 2021 (€21 Mil) to Dec. 2022 (€31 Mil) and increased from Dec. 2022 (€31 Mil) to Dec. 2023 (€31 Mil).


Exelixis Accounts Payable Historical Data

The historical data trend for Exelixis's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Accounts Payable Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.42 19.43 21.47 30.84 30.97

Exelixis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.47 23.99 24.78 30.97 23.98

Exelixis Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Exelixis Accounts Payable Related Terms

Thank you for viewing the detailed overview of Exelixis's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (FRA:EX9) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (FRA:EX9) Headlines

No Headlines